Hansa Biopharma: Increase of the number of shares and votes

Lund, Sweden, September 30, 2022. Hansa Biopharma AB “Hansa” or the “Company”, (Nasdaq Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today announces that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of September 2022.

As previously announced on 8 September 2022, Hansa Biopharma’s board of directors resolved to issue 850,769 class C shares, by virtue of the authorizations by the annual general meeting held on 30 June 2022. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

The purpose of the issue and repurchase was to ensure delivery of shares to employees and to secure potential social contributions arising as a result of the Company’s incentive programs in accordance with the resolutions from the annual general meeting held on 30 June 2022.

As of today, the total number of registered and outstanding shares of the Company amounts to 47,186,130, whereof 44,588,118 are ordinary shares and 2,598,012 are class C shares. As of today, the number of votes in the Company amounts to 44,847,919.2, and the registered share capital amounts to SEK 47,186,130.

This information is information that Hansa Biopharma AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on September 30, 2022, at 17:00 CEST

--ENDS—

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269
E-mail: klaus.sindahl@hansabiopharma.com 

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com.